Administration of Polymer nanoparticles (NPs)
Administration of Polymer nanoparticles (NPs) requires polymers that control how the drugs are released to the body. In the recent past, Polylactic, among other polymers, are increasingly applied along with (NPs). Polymers are synthetic, degradable, and biocompatible (Calzoni, Eleonora, et al. 4). It has become the most promising biopolymer since it can be developed from nontoxic and renewable material. Its ecofriendly properties make it suitable for use in the human body, with a wide range of applicability. Polylactic is derived from lactic acid, and the Food and Drug Administration approves the product of America in direct contact with body fluids. Polylactic material characteristics are good for the recovery of damaged materials, especially for cancer treatment, which has been a great challenge in medical engineering (Singhvi et al. 1620). Additionally, the lactic acid in Polylactic has antioxidant properties that protect free radicals produces by a cell in its lifetime from damaging body cells.
Polylactic has other properties such as mechanical strength, solubility, and heat processability that make it perfect for medical applications such as NPs: targeted drugs. Cancer therapies focus on the damaging cancer cell but damage healthy cells along the way. Polylactic properties enable passive targeting of cancer cells, ensuring cancer medication acts specifically on cancer cells. Polylactic encapsulates chemotherapeutics, enhancing antitumor activity by making their circulation time longer and enhance their stability protecting damages of the red blood cells. Passive targeting reduces anticancer drugs side effects such as weight loss as well as blood urea nitrogen, and improve tumor efficacy. Secondly, active targeting of anticancer drugs is enhanced by Polylactic. It helps hyaluronic acid that is overexpressed in breast stem cells and other regular cancer cells as an inhibitor for hedgehog signaling with superior antitumor activity. It is done through the internalization of in vitro and in vivo cells effective after drug withdrawal (Rezvantalab et al.). Finally, chemotherapeutic delivery with Polylactic increases its magnetic targeting of NPs towards the tumor site.
On the other hand, it is necessary to critically reflect on the clinical feasibility of chemotherapeutic drug delivery by polylactic. It has low encapsulation efficacy with the NPs associated with practical size variation, which relies on the mixing process. In the case of spraying treatment methods, polylactic particles are adhesive to the walls, which results in low productivity. In terms of microfluidic treatment, polylactic has a limited production scale associated with microchannel clogging as well as fouling. With such limitations, the researcher should critically reflect on the clinical feasibility of polylactic the development of NPs to match biomedical needs. Such advancements should not only be related to size optimization, loading, or release but other factors such as biocompatibility up calling as well as batch productivity. It would be important in clinical experimentation is targeted on tailored to a concrete clinical problem, with polylactic consistency. It related to drug loading efficacy, which has been a challenge to coming up with a practical size below 100 mm given an upscale process. Polylactic requires further purification and producibility in terms of the good manufacturing practice, necessary for a successful clinical translation. It is necessary that clinicians are aware of the pharmacokinetics as well as pharmacodynamics of NPs to avoid target accumulation and side effects associated with chemotherapeutic treatment.